Secondary prevention of macrovascular events with pioglitazone in diabetic patients: PROactive Study (PROspective pioglitAzone Clinical Trial in macroVascular Events);Makrovaskuläre Sekundärprävention mit pioglitazon bei diabetikern: PROactive Study (PROspective pioglitAzone Clinical Trial in macroVascular Events)

Internist

Volumn 48, Issue 1, 2007, Pages 89-92

  Seufert, J ^a  

^a UNIVERSITY OF FREIBURG   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

METFORMIN; ORAL ANTIDIABETIC AGENT; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA AGONIST; PIOGLITAZONE;

CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CLINICAL TRIAL; CONFIDENCE INTERVAL; DIABETES MELLITUS; HUMAN; MORBIDITY; MORTALITY; NON INSULIN DEPENDENT DIABETES MELLITUS; NOTE; RISK FACTOR;

AGED; DIABETES MELLITUS, TYPE 2; DIABETIC ANGIOPATHIES; DOUBLE-BLIND METHOD; FEMALE; FOLLOW-UP STUDIES; HUMANS; HYPOGLYCEMIC AGENTS; MALE; MIDDLE AGED; MULTICENTER STUDIES AS TOPIC; PPAR GAMMA; RANDOMIZED CONTROLLED TRIALS AS TOPIC; SURVIVAL RATE; THIAZOLIDINEDIONES;

EID: 33846585392     PISSN: 00209554     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00108-006-1777-6     Document Type: Note

References (5)

1. Bertoni AG, Hundley WG, Massing MW et al. (2004) Heart failure prevalence, incidence, and mortality in the elderly with diabetes. Diabetes Care 27: 699-703
2. Haffner SM, Lehto S, Ronnemaa T et al. (1998) Mortality from coronary heart disease in subjects with type 2 diabetes and in nondiabetic subjects with and without prior myocardial infarction. N Engl J Med 339: 229-234
3. Seufert J (2006) Cardiovascular outcome studies in type 2 diabetes therapy. Dtsch Arztebl 103: A 934-942
4. Yudkin JS, Freemantle N (2006) PROactive study. Lancet 367: 24-25; author reply 26-27
5. Yki-Jarvinen H (2005) The PROactive study: some answers, many questions. Lancet 366: 1241-1242